Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Artivion Inc (AORT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/16/2025: AORT (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 24.85% | Avg. Invested days 44 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.40B USD | Price to earnings Ratio - | 1Y Target Price 32.71 |
Price to earnings Ratio - | 1Y Target Price 32.71 | ||
Volume (30-day avg) 458984 | Beta 1.62 | 52 Weeks Range 21.97 - 32.33 | Updated Date 06/20/2025 |
52 Weeks Range 21.97 - 32.33 | Updated Date 06/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -5.49% | Operating Margin (TTM) -0.69% |
Management Effectiveness
Return on Assets (TTM) 1.54% | Return on Equity (TTM) -7.26% |
Valuation
Trailing PE - | Forward PE 94.34 | Enterprise Value 1721668820 | Price to Sales(TTM) 3.58 |
Enterprise Value 1721668820 | Price to Sales(TTM) 3.58 | ||
Enterprise Value to Revenue 4.41 | Enterprise Value to EBITDA 48.82 | Shares Outstanding 47037100 | Shares Floating 37689051 |
Shares Outstanding 47037100 | Shares Floating 37689051 | ||
Percent Insiders 5.13 | Percent Institutions 97.31 |
Analyst Ratings
Rating 4.67 | Target Price 32.33 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Artivion Inc
Company Overview
History and Background
Artivion, Inc., formerly CryoLife, Inc., was founded in 1984. It focuses on developing, manufacturing, and distributing medical devices and implantable human tissues used in cardiac and vascular surgical procedures.
Core Business Areas
- Aortic: Offers a comprehensive portfolio of aortic stent grafts, surgical grafts, and related technologies for the treatment of aortic diseases.
- Cardiac Surgery: Focuses on products used in heart valve repair and replacement, as well as other cardiac surgical procedures.
- Perfusion: Provides products used during cardiopulmonary bypass, including oxygenators and blood management systems.
Leadership and Structure
Pat Mackin serves as Chairman, President, and Chief Executive Officer. The company has a typical corporate structure with functional departments such as R&D, Sales, Marketing, Operations, and Finance.
Top Products and Market Share
Key Offerings
- EACT Edge Graft: An endovascular abdominal aortic aneurysm (AAA) repair graft. Competitors include Medtronic (MDT) and Cook Medical. Market Share data is difficult to find as there is no exact publicly available data, but Artivion is a smaller player than Medtronic in the overall aortic stent graft market.
- BioGlue Surgical Adhesive: A surgical adhesive used to bond tissues. Competitors include Baxter International (BAX) and Ethicon (JNJ). Precise market share data is not readily available, but BioGlue is a well-established product in its market.
- On-X Aortic Heart Valve: A mechanical heart valve for aortic valve replacement. Competitors include Medtronic (MDT), Abbott (ABT), and Edwards Lifesciences (EW). Market Share data is difficult to find as there is no exact publicly available data, but Artivion is a smaller player than Medtronic, Abbott, and Edwards in the overall mechanical valve market.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulatory oversight, and competition. Demand is driven by aging populations, technological advancements, and increasing healthcare spending.
Positioning
Artivion focuses on niche markets within cardiac and vascular surgery. Its competitive advantage lies in its specialized product portfolio and expertise in tissue processing and device development.
Total Addressable Market (TAM)
The cardiovascular device market is estimated to be worth billions of dollars annually. Artivion's TAM is a subset of this, focusing on aortic and cardiac surgery, which is estimated to be around $5 billion. They are positioned to capture a small percentage, with plans to grow with the market.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio
- Strong brand reputation in certain niches
- Experienced management team
- Focus on innovation and product development
Weaknesses
- Smaller size compared to larger competitors
- Dependence on specialized markets
- Regulatory risks associated with medical devices
- Limited financial resources compared to larger competitors
Opportunities
- Expansion into new geographic markets
- Development of new products and technologies
- Acquisition of complementary businesses
- Increased demand for minimally invasive procedures
Threats
- Intense competition from larger companies
- Price pressure from healthcare providers
- Changes in regulatory requirements
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- MDT
- ABT
- JNJ
- BSX
- EW
Competitive Landscape
Artivion faces significant competition from larger, well-established medical device companies. Its competitive advantage lies in its specialized product portfolio and focus on niche markets. Its smaller size can be a disadvantage in terms of financial resources and market reach.
Major Acquisitions
Jotec AG
- Year: 2017
- Acquisition Price (USD millions): 225
- Strategic Rationale: Expanded Artivion's aortic product portfolio and geographic reach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been steady, driven by product innovation and market expansion.
Future Projections: Analyst estimates vary, but generally project continued growth in revenue and earnings per share (EPS).
Recent Initiatives: Focus on expanding its product portfolio through internal development and acquisitions.
Summary
Artivion is a specialized medical device company with a focus on aortic and cardiac surgery. It has a strong product portfolio and experienced management team, but it is smaller than its competitors. The company is focused on innovation and market expansion, but it needs to navigate regulatory risks and competitive pressures. Its future hinges on its ability to develop and commercialize new products and expand its geographic reach.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Artivion Inc
Exchange NYSE | Headquaters Kennesaw, GA, United States | ||
IPO Launch date 1993-02-12 | Chairman, President & CEO Mr. James Patrick Mackin | ||
Sector Healthcare | Industry Medical Devices | Full time employees 1600 | Website https://artivion.com |
Full time employees 1600 | Website https://artivion.com | ||
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products. It also offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; Tuva BX, a balloon-expandable peripheral stent graft to treat arterial ruptures, aneurysms, and other peripheral vascular system pathologies; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves, and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures for mitral chordal replacement; and pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.